FOV407 / Foventa Therapeutics, J&J - LARVOL DELTA

Exonate Becomes Foventa Therapeutics (Yahoo Finance) - "The new name, which takes inspiration from the fovea, marks the company's transition to focus on clinical development in non-proliferative diabetic retinopathy...FOV407 has been evaluated in Phase Ib/IIa clinical studies, and a Phase IIb study in NPDR is in preparation, with a design validated through a Type C meeting with the US Food and Drug Administration."

Commercial • FDA event • Diabetic Macular Edema • Diabetic Retinopathy

High retinal and low systemic exposure of EXN407 eye drops in humans, a new topical therapeutic for the treatment of diabetic macular edema (DME) (ARVO 2024) - P1/2 | "EXN407, while having high retinal exposure, exhibits very low systemic exposure, with a maximal plasma concentration well below the levels required for efficacy (Cmax free concentration <0.001% in vitro IC50), indicating that the effect of EXN407 on retinopathy and macular thickness is due to local topical, not systemic, action."

Age-related Macular Degeneration • Diabetic Macular Edema • Macular Degeneration • Ophthalmology • Retinal Disorders • Wet Age-related Macular Degeneration • SRPK1

A double-masked, Placebo-Controlled, Phase 1b/2a Study of EXN407 Eye Drops in Patients with Mild Center Involving Diabetic Macular Edema (DME) (ARVO 2024) - "Topical EXN407, BID (1.5mg/mL) was safe and well tolerated in subjects with mild, centrally-involved DME. The potential therapeutic effects of EXN407 warrant further investigation."

Clinical • P1/2 data • Age-related Macular Degeneration • Diabetic Macular Edema • Ophthalmology • SRPK1

A Study to Evaluate the Safety and Tolerability of EXN407 (clinicaltrials.gov) - P1/2 | N=48 | Completed | Sponsor: Exonate Limited | Active, not recruiting ➔ Completed

Trial completion • Diabetes • Diabetic Macular Edema • Macular Edema • Metabolic Disorders • Ophthalmology

A Study to Evaluate the Safety and Tolerability of EXN407 (clinicaltrials.gov) - P1/2 | N=48 | Active, not recruiting | Sponsor: Exonate Limited | Recruiting ➔ Active, not recruiting | Trial primary completion date: Mar 2022 ➔ Oct 2022

Enrollment closed • Trial primary completion date • Diabetes • Diabetic Macular Edema • Macular Edema • Metabolic Disorders • Ophthalmology

A Study to Evaluate the Safety and Tolerability of EXN407 (clinicaltrials.gov) - P1/2; N=48; Recruiting; Sponsor: Exonate Limited; Trial primary completion date: Nov 2021 ➔ Mar 2022

Clinical • Trial primary completion date • Diabetes • Diabetic Macular Edema • Macular Edema • Metabolic Disorders • Ophthalmology

A Study to Evaluate the Safety and Tolerability of EXN407 (clinicaltrials.gov) - P1/2; N=48; Recruiting; Sponsor: Exonate Limited; Not yet recruiting ➔ Recruiting

Clinical • Enrollment open • Diabetes • Diabetic Macular Edema • Macular Edema • Metabolic Disorders • Ophthalmology

A Study to Evaluate the Safety and Tolerability of EXN407 (clinicaltrials.gov) - P1/2; N=48; Not yet recruiting; Sponsor: Exonate Limited

Clinical • New P1/2 trial • Diabetes • Diabetic Macular Edema • Macular Edema • Metabolic Disorders • Ophthalmology